Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Testicular cancer

Serum tumour markers for testicular cancer recurrence

The current serum tumour markers α-fetoprotein, human chorionic gonadotrophin, and lactate dehydrogenase show limited value for testicular cancer relapse detection. A recent study highlights that false-positive elevations in follow-up monitoring are common and, conversely, many patients do not have elevations despite proven relapse. These findings highlight the potential for circulating microRNAs to be used as improved biomarkers for relapse detection.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Kollmannsberger, C. et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J. Clin. Oncol. 33, 51–57 (2015).

    Article  PubMed  Google Scholar 

  2. Javadpour, N. & Soares, T. False-positive and false-negative alpha-feto protein and human chorionic gonadotropin assays in testicular cancer: a double blind study. Cancer 48, 2279–2281 (1981).

    Article  CAS  PubMed  Google Scholar 

  3. Germà, J. R., Llanos, M., Tabernero, J. M. & Mora, J. False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer 72, 2491–2494 (1993).

    Article  PubMed  Google Scholar 

  4. Germa, J. R., Arcusa, A. & Casamitjana, R. False elevations of human chorionic gonadotropin associated to iatrogenic hypogonadism in gonadal germ cell tumors. Cancer 60, 2489–2493 (1987).

    Article  CAS  PubMed  Google Scholar 

  5. Fischer, S. et al. The value of tumour markers in the detection of relapse—lessons learned from the Swiss Austrian German Testicular Cancer Cohort study. Eur. Urol. Open Sci. 50, 57–60 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Murray, M. J., Huddart, R. A. & Coleman, N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat. Rev. Urol. 13, 715–725 (2016).

    Article  CAS  PubMed  Google Scholar 

  7. Leão, R. et al. Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review. Eur. Urol. 80, 456–466 (2021).

    Article  PubMed  Google Scholar 

  8. Fankhauser, C. D. et al. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br. J. Cancer 126, 1140–1144 (2022).

    Article  CAS  PubMed  Google Scholar 

  9. Lafin, J. et al. Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range. Preprint at Research Square (2023).

  10. Fern, L. A. et al. Pre-implementation assessment of the acceptability of using circulating microRNAs for follow-up of malignant germ-cell tumors. Clin. Genitourin. Cancer 19, 381–387 (2021).

    Article  PubMed  Google Scholar 

Download references


The authors acknowledge grant funding from the National Cancer Institute of the National Institutes of Health (reference PAR-18-317; UH3CA240688), the St. Baldrick’s Foundation (reference 358099) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). They are grateful for support from the Max Williamson Fund and from Christiane and Alan Hodson, in memory of their daughter Olivia.

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Matthew J. Murray or Nicholas Coleman.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murray, M.J., Scarpini, C.G. & Coleman, N. Serum tumour markers for testicular cancer recurrence. Nat Rev Urol 20, 459–460 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer